Lonza Signs Agreement with Index Ventures for Biological Products - - BioPharm International

ADVERTISEMENT

Lonza Signs Agreement with Index Ventures for Biological Products



Lonza, a custom biologics manufacturing organization and Index Ventures, a venture capital investment firm, have signed an agreement for process development and cGMP production for all biological products in the portfolio of companies where Index is the major investor. Over the course of the agreement, additional development and manufacturing projects will be added to the product list, as future investments are made by Index.

Source: Lonza

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here